Rachel,
Actual DUPIXENT patient
since 2017.
Individual results may vary.
BeforeTreatment
After Treatment
with dupixent
at 16 weeks
Before
Treatment
After Treatment
with dupixent
at 16 weeks
Actual real-world DUPIXENT patients shown; not clinical trial patients. Additional factors (including possible use of other treatments) may have impacted results. Individual results may vary.
Results from 2 clinical trials of adults with moderate-to-severe eczema at 16 weeks:
37% on DUPIXENT vs
9% not on DUPIXENT
38% on DUPIXENT vs
11% not on DUPIXENT
48% on DUPIXENT vs 13% not on DUPIXENT
33% on DUPIXENT vs 7% not on DUPIXENT
Great! Sign up for DUPIXENT MyWay®, our patient support program, to access program services and get one-on-one support every step of the way, including help with filling your first prescription.
If you're still struggling with moderate-to-severe eczema, maybe it's time to change the conversation.
Answer a few short questions about your eczema symptoms and treatment goals. We’ll turn it into a personalized discussion guide you can use at your next visit.
Specialists like dermatologists or allergists often have more experience treating moderate-to-severe eczema and can help create a personalized care plan for you.
Results from a clinical trial that studied DUPIXENT for 12 months:
At 4 months: 39% on DUPIXENT +
TCS vs 12% on TCS only
At both 4 months and 12 months:
22% on DUPIXENT + TCS vs 7%
on TCS only
At 12 months: 51% on DUPIXENT + TCS
vs 13% on TCS only
At 2 weeks: 18% on DUPIXENT +
TCS vs 8% on TCS only
TCS, topical corticosteroids.
Long-term safety results for adults continuing on DUPIXENT in an extension study through 5 years were consistent with those seen in the original clinical trials.
Most common side effects include:
View the possible side effects of DUPIXENT
What you should know about the adult patients in these studies:
Feel like you're struggling with your symptoms?
Sign up for information that can help.